Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin
Article first published online: 11 OCT 2010
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Molecular Nutrition & Food Research
Volume 55, Issue 3, pages 495–503, March 2011
How to Cite
Kakkar, V., Singh, S., Singla, D. and Kaur, I. P. (2011), Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol. Nutr. Food Res., 55: 495–503. doi: 10.1002/mnfr.201000310
- Issue published online: 2 MAR 2011
- Article first published online: 11 OCT 2010
- Manuscript Accepted: 26 AUG 2010
- Manuscript Revised: 16 AUG 2010
- Manuscript Received: 8 JUL 2010
- Council of Scientific and Industrial Research (CSIR), New Delhi, India. Grant Number: 110012
- Liquid–liquid extraction;
- Solid lipid nanoparticles
Scope: Curcumin, a molecule with pluripharmacological properties, was loaded into solid lipid nanoparticles (SLNs) with a view to improve its oral bioavailability (BA).
Methods and results: Curcumin-loaded solid lipid nanoparticles (C-SLNs) with an average particle size of 134.6 nm and a total drug content of 92.33±1.63% was produced using a microemulsification technique. The particles were spherical in shape, with high drug entrapment of 81.92±2.91% at 10% drug loading. The in vitro release was predominantly by diffusion phenomenon and was prolonged up to 7 days. No significant variation in particle size and curcumin content of C-SLNs was observed, upon storage, over a period of 12 months at 5±3°C. In vivo pharmacokinetics performed after oral administration of C-SLNs (50, 25, 12.5 and 1 mg/kg dose) and (free) solubilized curcumin (C-S; 50 mg/kg), using a validated LC-MS/MS method in rat plasma revealed significant improvement (at p<0.05) in BA (39 times at 50 mg/kg; 155 times at 1 mg/kg; and, 59 and 32 times at 12.5 and 25 mg/kg, respectively) after administration of C-SLNs at all the doses with respect to C-S.
Conclusions: Enhanced and reliable BA will help in establishing its therapeutic usefulness especially for neurodegenerative and cancerous disorders in humans.